PROS1 and myeloproliferative disorder: Plasma from IFN-α-treated MPN patients also displayed significantly increased activity of fibrinogen and the coagulation factor FVIII, as well as reduced protein S activity, indicating a shift in MPN patients to a more procoagulant phenotype.